Guardant Well being director Tariq Musa sells shares price $4,359

Tariq Musa, a director at Guardant Well being , Inc. (NASDAQ:GH), not too long ago reported the sale of 116 shares of the corporate’s frequent inventory. The transaction, which occurred on January 17, 2025, was executed at a worth of $37.58 per share, totaling roughly $4,359. The inventory has proven exceptional energy, delivering a 58% return over the previous 12 months, and presently trades close to its 52-week excessive at $45.13. In line with InvestingPro evaluation, the corporate’s present market capitalization stands at $5.56 billion. Following this sale, Musa holds 2,944 shares within the firm. The submitting was submitted to the SEC on January 21, 2025. Wall Road analysts preserve a bullish outlook on the inventory, with worth targets starting from $34 to $60. For deeper insights into insider buying and selling patterns and complete evaluation, InvestingPro subscribers can entry detailed analysis experiences protecting 1,400+ US shares, together with Guardant Well being.

In different current information, Guardant Well being has been the main focus of quite a few analyst scores. Raymond (NSE:RYMD) James reaffirmed its Outperform ranking with a worth goal of $39, whereas TD Cowen maintained a Purchase ranking with a goal of $42. BTIG raised its worth goal to $55, and Canaccord Genuity held agency with a $42 goal. These scores replicate a optimistic outlook for Guardant Well being, notably with current developments in Medicare protection for its Reveal check, designed to detect colon most cancers recurrence.

The corporate’s robust income development of 29.2% during the last 12 months was highlighted by analysts. They anticipate that the expanded Medicare protection and enhancements in pricing may result in a surge in medical volumes, exceeding 20%. Nevertheless, the corporate shouldn’t be anticipated to attain profitability this 12 months.

Analysts additionally famous Guardant Well being’s partnership with Boehringer Ingelheim to hunt regulatory approval for Guardant360® CDx, a liquid biopsy check. That is thought of a key growth for the corporate. Traders are awaiting Guardant Well being’s fourth-quarter outcomes for additional insights into its monetary well being and operational progress.

These current developments underscore Guardant Well being’s important strides within the healthcare sector, with a specific concentrate on superior diagnostics applied sciences. The corporate maintains a wholesome monetary place with a present ratio of 6.22, indicating robust liquidity to assist its development initiatives.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.